ZSTK474 | PI3K | AmBeed-信号通路专用抑制剂

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

产品名称	C2β ↓ ↑	p110α ↓ ↑	p110β ↓ ↑	p110γ ↓ ↑	p110δ ↓ ↑	PI3K ↓ ↑	Vps34 ↓ ↑	其他靶点	纯度
A66	+ C2β, IC50: 462 nM	++ p110α, IC50: 32 nM							99%+
Taselisib	+ C2β, IC50: 292 nM	++++ PI3Kα, Ki: 0.29 nM	+++ PI3Kβ, Ki: 9.1 nM	++++ PI3Kγ, Ki: 0.97 nM	++++ PI3Kδ, Ki: 0.12 nM		+ hVps34, IC50: 374 nM		99%+
Gedatolisib		++++ PI3Kα, IC50: 0.4 nM		+++ PI3Kγ, IC50: 5.4 nM				mTOR	99%
HS-173		++++ PI3Kα , IC50: 0.8 nM							99%+
Serabelisib		+++ PI3Kα, IC50: 21 nM							99%+
GNE-477		++++ PI3Kα, IC50: 4 nM						mTOR	99%
YM-201636		+ p110α, IC50: 3.3 μM						PIKfyve	98%
AS-252424		+ PI3Kα, IC50: 935 nM		++ PI3Kγ, IC50: 33 nM					99%
Alpelisib		+++ PI3Kα, IC50: 5 nM							99%+
AS-604850		+ PI3Kα, IC50: 4.5 μM		+ PI3Kγ, IC50: 0.25 μM					99%
SF2523		++ PI3Kα, IC50: 34 nM		++ PI3Kγ, IC50: 158 nM				DNA-PK,mTOR	99%+
Inavolisib		++++ PI3K alpha, IC50: 0.038 nM							99%+
Bimiralisib		++++ PI3Kα, Kd: 1.5 nM	+++ PI3Kβ, Kd: 11 nM	++ PI3Kγ, Kd: 25 nM	++ PI3Kδ, Kd: 25 nM			mTOR	99%+
GSK1059615		++++ PI3Kα, IC50: 0.4 nM	++++ PI3Kβ, IC50: 0.6 nM	+++ PI3Kγ, IC50: 5 nM	++++ PI3Kδ, IC50: 2 nM			mTOR	98%
GSK2636771			✔						99%
Fimepinostat		+++ PI3Kα, IC50: 19 nM	++ PI3Kβ, IC50: 54 nM		++ PI3Kδ, IC50: 39 nM				99%+
VS-5584		++++ PI3Kα, IC50: 2.6 nM	+++ PI3Kβ, IC50: 21 nM	++++ PI3Kγ, IC50: 3.0 nM	++++ PI3Kδ, IC50: 2.7 nM			mTOR	98%
Dactolisib		++++ p110α1, IC50: 4 nM	++ p110β, IC50: 75 nM	+++ p110γ, IC50: 5 nM	+++ p110δ, IC50: 7 nM				98+%
PI-103		++++ p110α, IC50: 2 nM	++++ p110β, IC50: 3 nM	+++ p110γ, IC50: 15 nM	++++ p110δ, IC50: 3 nM			DNA-PK,mTOR	99%+
PI-3065			+ p110β, IC50: 1078 nM		+++ p110δ, IC50: 15 nM				99%+
Voxtalisib		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			DNA-PK,mTOR	99%+
AZD-8835		+++ PI3Kα, IC50: 6.2 nM	+ PI3Kβ, IC50: 431 nM	++ PI3Kγ, IC50: 90 nM	+++ PI3Kδ, IC50: 5.7 nM				99%
Pilaralisib analogue		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 36 nM	+++ PI3Kγ, IC50: 23 nM	++ PI3Kδ, IC50: 36 nM				99%+
ZSTK474		+++ PI3Kα, IC50: 16 nM	++ PI3Kβ, IC50: 44 nM	++ PI3Kγ, IC50: 49 nM	+++ PI3Kδ, IC50: 4.6 nM	++ PI3K, IC50: 37 nM			98%
AS-605240		++ PI3Kα, IC50: 60 nM	+ PI3Kβ, IC50: 270 nM	+++ PI3Kγ, IC50: 8 nM	+ PI3Kδ, IC50: 300 nM				98%
TGX-221			+++ p110β, IC50: 5 nM		++ p110δ, IC50: 0.1 μM				99%+
PF-04691502		++++ PI3Kα, Ki: 1.8 nM	++++ PI3Kβ, Ki: 2.1 nM	++++ PI3Kγ, Ki: 1.9 nM	++++ PI3Kδ, Ki: 1.6 nM			mTOR	98+%
GDC-0084		++++ PI3Kα, Ki app: 2 nM	++ PI3Kβ, Ki app: 46 nM	+++ PI3Kγ, Ki app: 10 nM	++++ PI3Kδ, Ki app: 3 nM			mTOR	99%+
Buparlisib		++ p110α, IC50: 52 nM	+ p110β, IC50: 166 nM	+ p110γ, IC50: 262 nM	++ p110δ, IC50: 116 nM		+ Vps34, IC50: 2.4 μM	mTOR	98%
LY294002		+ p110α, IC50: 0.5 μM	+ p110β, IC50: 0.97 μM		+ p110δ, IC50: 0.57 μM			DNA-PK	99%+
AZD 6482		+ PI3Kα, IC50: 870 nM	+++ PI3Kβ, IC50: 10 nM		++ PI3Kδ, IC50: 80 nM			DNA-PK	99%+
Pictilisib		++++ p110α, IC50: 3 nM	++ p110β, IC50: 33 nM	++ p110γ, IC50: 75 nM	++++ p110δ, IC50: 3 nM			mTOR	99%+
PKI-402		++++ PI3Kα, IC50: 2 nM	+++ PI3Kβ, IC50: 7 nM	+++ PI3Kγ, IC50: 16 nM	+++ PI3Kδ, IC50: 14 nM			mTOR	98%
Copanlisib		++++ PI3Kα, IC50: 0.5 nM	++++ PI3Kβ, IC50: 3.7 nM	+++ PI3Kγ, IC50: 6.4 nM	++++ PI3Kδ, IC50: 0.7 nM				99%+
Omipalisib		++++ p110α, Ki: 0.019 nM	++++ p110β, Ki: 0.13 nM	++++ p110γ, Ki: 0.06 nM	++++ p110δ, Ki: 0.024 nM				99%+
Izorlisib		+++ PI3Kα, IC50: 14 nM	++ PI3Kβ, IC50: 0.12 μM	++ PI3Kγ, IC50: 36 nM	+ PI3Kδ, IC50: 0.50 μM				99%+
AZD8186		++ PI3Kα, IC50: 35 nM	++++ PI3Kβ, IC50: 4 nM		+++ PI3Kδ, IC50: 12 nM				99%
KU-0060648		++++ PI3Kα, IC50: 4 nM	++++ PI3Kβ, IC50: 0.5 nM	+ PI3Kγ, IC50: 0.59 μM	++++ PI3Kδ, IC50: 0.1 nM			DNA-PK	98%
Apitolisib		+++ p110α, IC50: 5 nM	++ p110β, IC50: 27 nM	+++ p110γ, IC50: 14 nM	+++ p110δ, IC50: 7 nM			mTOR	98%+
CZC24832			+ PI3Kβ, IC50: 1.1 μM	++ PI3Kγ, IC50: 27 nM					98+%
BGT226 maleate		++++ PI3Kα, IC50: 4 nM	++ PI3Kβ, IC50: 63 nM	++ PI3Kγ, IC50: 38 nM				mTOR	99%+
TG 100713		++ PI3Kα, IC50: 165 nM	+ PI3Kβ, IC50: 215 nM	++ PI3Kγ, IC50: 50 nM	+++ PI3Kδ, IC50: 24 nM				98%+
PI3K-IN-1		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			DNA-PK,mTOR	98+%
TG100-115		+ PI3Kα, IC50: 1.3 μM	+ PI3Kβ, IC50: 1.2 μM	++ PI3Kγ, IC50: 83 nM	+ PI3Kδ, IC50: 235 nM				98%
PIK-90		+++ PI3Kα, IC50: 11 nM	+ PI3Kβ, IC50: 350 nM	+++ PI3Kγ, IC50: 18 nM	++ PI3Kδ, IC50: 58 nM				99%+
PIK-294			+ p110β, IC50: 490 nM	++ p110γ, IC50: 160 nM	+++ p110δ, IC50: 10 nM				99%+
Duvelisib			++++ PI3Kβ, Ki: 1564 pM	++ PI3Kγ, Ki: 243 pM	++++ PI3Kδ, Ki: 23 pM				99%+
GDC-0326		++++ PI3Kα, Ki: 0.2 nM	++ PI3Kβ, Ki: 26.6 nM	+++ PI3Kγ, Ki: 10.2 nM	++++ PI3Kδ, Ki: 4 nM				98%
Quercetin Dihydrate			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM				95%
Quercetin			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM			Src,PKC,Sirtuin	95%
Leniolisib		+ PI3Kα, IC50: 0.244 μM	+ PI3Kβ, IC50: 0.424 μM	+ PI3Kγ, IC50: 2.23 μM	+++ PI3Kδ, IC50: 0.011 μM			DNA-PK	99%+
PIK-108			✔						99%
Eganelisib				+++ PI3Kγ, IC50: 16 nM					99%+
CAY10505				✔					99%
IPI-3063					++++ p110δ, IC50: 2.5 nM				99%
Nemiralisib					++++ PI3Kδ, pKi: 9.9				99%+
PF-4989216		++++ p110α, IC50: 2 nM		++ p110γ, IC50: 65 nM	++++ p110δ, IC50: 1 nM				99%+
PIK-75 HCl		+++ p110α, IC50: 5.8 nM		++ p110γ, IC50: 76 nM	+ p110δ, IC50: 0.51 μM			DNA-PK	99%+
Tenalisib				++ PI3Kγ, IC50: 33.2 nM	++ PI3Kδ, IC50: 24.5 nM				98%
Acalisib					+++ p110δ, IC50: 14 nM				99%+
Umbralisib					+++ PI3Kδ, IC50: 22.2 nM				99%+
AMG319				+ PI3Kγ, IC50: 850 nM	+++ PI3Kδ, IC50: 18 nM				99%
IC-87114				+ PI3Kγ, IC50: 29 μM	+ PI3Kδ, IC50: 0.5 μM				99%+
Idelalisib				++ p110γ, IC50: 89 nM	++++ p110δ, IC50: 2.5 nM				98%
PIK-293				+ p110γ, IC50: 10 μM	+ p110δ, IC50: 0.24 μM				99%+
Vps34-PIK-III					+ PI3Kδ, IC50: 1.2μM		+++ Vps34, IC50: 0.018μM		99%+
GSK2292767					✔				98%
Seletalisib				+ PI3Kγ, IC50: 282 nM	+++ PI3Kδ, IC50: 12 nM				99%+
P110δ-IN-1					++++ P110δ, IC50: 0.6 nM				99%
PI3Kδ-IN-5					++++ PI3Kδ, IC50: 0.9 nM				99%
SRX3207		+ PI3K alpha, IC50: 244 nM		+ PI3K gamma, IC50: 9790 nM	+ PI3K delta, IC50: 388 nM			Syk	98%
Parsaclisib HCl					++++ PI3Kδ, IC50: 1 nM				98%
IHMT-PI3Kδ-372					+++ PI3Kδ, IC50: 14 nM				98%
Trigonelline						✔		Akt	99%+
Wortmannin						++++ PI3K, IC50: 3 nM		MLCK,DNA-PK	99%+
Samotolisib						✔		DNA-PK	99%+
GNE-317						✔			99%+
Oroxin B						✔		Akt,PTEN	99%+
NU 7026						+ PI3K, IC50: 13 μM		DNA-PK	98+%
Deguelin						✔		Akt	99%+
Ailanthone						✔		Akt,CDK,ATM/ATR	98%
Resibufogenin						✔		ROS	98%
KU-57788						+ PI3K, IC50: 5 μM		DNA-PK,mTOR	99%+
Cinobufagine						✔		Akt	99%
α-Linolenic acid						✔			97% (GC)
MTX-211						✔		EGFR	98%
PI3K/mTOR Inhibitor-2						++++ PI3K, IC50: 3.4 nM		mTOR	99%+
SPP-86						✔			99%+
(E)-Akt inhibitor-IV						✔			98%
Vps34-IN-1							++ Vps34, IC50: 25 nM		98%
SAR405							++++ Vps34, IC50: 1.2 nM		98+%
3-Methyladenine				+ PI3Kγ, IC50: 60 μM			+ Vps34, IC50: 25 μM	Autophagy	98%
Vps34-IN-4							+++ VPS34, IC50: 15 nM		98%+
Autophinib							+++ Vps34, IC50: 19 nM	Autophagy	99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

靶点	p110γ PI3Kγ, IC50:49 nM p110β PI3Kβ, IC50:44 nM p110α PI3Kα, IC50:16 nM PI3K PI3K, IC50:37 nM p110δ PI3Kδ, IC50:4.6 nM
描述	Phosphatidylinositol 3-kinase (PI3K), which is active in signal transduction, generates phosphatidylinositol-3,4,5-tris-phosphate (PIP₃) by phosphorylating phosphatidylinositol-4,5-bisphosphate. PI3K is involved in various cellular processes, including cell survival, vesicle transport, and cytoskeletal rearrangement^[3]. ZSTK474, a novel s-triazine derivative, is an ATP-competitive pan-class I PI3K inhibitor with IC₅₀s of 16 nM, 44 nM, 4.6 nM and 49 nM for PΙ3Κα, PI3Kβ, PI3Kδ and PI3Kγ, respectively^[4]. The mean logarithm of GI₅₀ for ZSTK474 was −6.49 at 0.32 μM, which was substantially lower than that observed with LY294002 or wortmannin, indicating that ZSTK474 had stronger cell growth inhibitory activity than either of these two known PI3K inhibitors. At concentration of 1 μM, ZSTK474 reduced the PI3K activity to 4.7% of the untreated control activity. When murine embryonic fibroblast cells were incubated for 15 minutes with 1 μM ZSTK474 before the addition of platelet-derived growth factor, both membrane ruffling and the formation of PIP₃ , a measure of PI3K activity, were blocked. At 10 μM, a higher concentration than its GI₅₀, ZSTK474 induced apoptosis in OVCAR3 cells. When administered orally for 2 weeks, ZSTK474 inhibited the growth of subcutaneously implanted mouse B16F10 melanoma tumors in a dose-dependent manner. Almost complete tumor growth inhibition (i.e., tumor regression) was observed at higher dosages^[3].
作用机制	There are three hydrogen-bonding interactions between PI3K and ZSTK474 (i.e., K802 NZ, one of the morpholino oxygens; S806 OG, the other morpholino oxygen; and V882 NH, the benzimidazole nitrogen)^[3].

Cell Line MCF7 cells A431 cells LM-EV BT549-EV REH cells MOLT-4 cells MOLM-14 cells K562 cells RAW264.7 cells mature osteoclasts Huh7 MHCC97H	Concentration	Treated Time	Description	References
MCF7 cells	10 µM	1 h	Inhibition of PI3K signaling pathway to observe its effect on ERK activation	Nat Commun. 2018 Nov 7;9(1):4673.
A431 cells	1 µM	6 h	To evaluate the effect of ZSTK474 on apoptosis in A431 cells, results showed that CD151 knockdown increased ZSTK474-induced apoptosis.	Cell Mol Life Sci. 2019 Apr;76(8):1595-1604.
LM-EV	30 μM	7 days	To study the effect of ZSTK474 on the viability of LM-EV cells in suspension culture, results showed that ZSTK474 significantly reduced the viability of LM-EV cells	Breast Cancer Res. 2016 Aug 5;18(1):81.
BT549-EV	30 μM	7 days	To study the effect of ZSTK474 on the viability of BT549-EV cells in suspension culture, results showed that ZSTK474 significantly reduced the viability of BT549-EV cells	Breast Cancer Res. 2016 Aug 5;18(1):81.
REH cells	4 µM	48 h	To evaluate the synergistic anticancer effect of ZSTK474 combined with AZD0364 on REH cells, the results showed that the combination treatment significantly reduced cell viability, increased ROS production, and induced apoptosis.	Antioxidants (Basel). 2020 Jul 17;9(7):633.
MOLT-4 cells	0.5 µM	48 h	To evaluate the synergistic anticancer effect of ZSTK474 combined with AZD0364 on MOLT-4 cells, the results showed that the combination treatment significantly reduced cell viability, increased ROS production, and induced apoptosis.	Antioxidants (Basel). 2020 Jul 17;9(7):633.
MOLM-14 cells	0.5 µM	48 h	To evaluate the synergistic anticancer effect of ZSTK474 combined with AZD0364 on MOLM-14 cells, the results showed that the combination treatment significantly reduced cell viability, increased ROS production, and induced apoptosis.	Antioxidants (Basel). 2020 Jul 17;9(7):633.
K562 cells	8 µM	48 h	To evaluate the anticancer effect of ZSTK474 combined with AZD0364 on K562 cells, the results showed that the combination treatment had an antagonistic effect on K562 cells.	Antioxidants (Basel). 2020 Jul 17;9(7):633.
RAW264.7 cells	0.1 μM	30 min	ZSTK474 suppressed the phosphorylation of Akt induced by sRANKL, indicating its inhibitory effect on the PI3-K/Akt signaling pathway.	Arthritis Res Ther. 2010;12(3):R92.
mature osteoclasts	0.1 μM	72 h	ZSTK474 completely inhibited the bone-resorbing activity of mature osteoclasts.	Arthritis Res Ther. 2010;12(3):R92.
Huh7	5 μM	24 h	The combination of ZSTK474 and PIK3C3 inhibitor significantly suppressed the expression of stemness genes and effectively reduced the proportion of CD133+ cells.	Cell Death Dis. 2020 Jun 8;11(6):427.
MHCC97H	5 μM	24 h	The combination of ZSTK474 and PIK3C3 inhibitor significantly suppressed the expression of stemness genes and effectively reduced the proportion of CD133+ cells.	Cell Death Dis. 2020 Jun 8;11(6):427.

Species C57BL/6 mice Mice Mice Nude mice	Animal Model Cerebral ischemia/reperfusion injury model Cerebral ischemia/reperfusion injury model Collagen-induced arthritis (CIA) model Subcutaneous xenograft model	Administration	Dosage	Frequency	Description	References
C57BL/6 mice	Cerebral ischemia/reperfusion injury model	Oral	200 mg/kg	Once daily for 3 days	ZSTK474 alleviated neurological deficits, reduced infarct volume, and shifted the phenotype of microglia/macrophages, inhibiting the inflammatory response in the cerebral ischemia/reperfusion injury model.	J Neuroinflammation. 2016 Aug 22;13(1):192
Mice	Cerebral ischemia/reperfusion injury model	Oral gavage	200 mg/kg	Once daily for 3 days	ZSTK474 alleviated neurological deficits, reduced infarct volume, and improved neurological function in the cerebral ischemia/reperfusion injury model.	J Neuroinflammation. 2016 Aug 22;13(1):192
Mice	Collagen-induced arthritis (CIA) model	Oral	25, 50, 100 mg/kg	Once daily until the end of the experiment	ZSTK474 significantly alleviated arthritis symptoms in the CIA model, reduced inflammatory cell infiltration and cartilage/bone destruction, and significantly decreased osteoclast formation.	Arthritis Res Ther. 2010;12(3):R92.
Nude mice	Subcutaneous xenograft model	Oral	200 mg/kg	Once daily for 10 days	The combination of ZSTK474 and PIK3C3 inhibitor significantly suppressed tumor growth and reduced the proportion of CD133+ cells in tumors.	Cell Death Dis. 2020 Jun 8;11(6):427.

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01682473	Neoplasms	Phase 1	Completed	-	Japan ... 展开 >> National Cancer Center Hospital East Kashiwa-city, Chiba, Japan The Cancer Institute Hospital of JFCR Koto-ku, Tokyo, Japan 收起 <<
NCT01280487	Neoplasms	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Boston, Massachusetts, United States United States, Missouri Washington University St Louis, Missouri, United States United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States 收起 <<

CAS号	475110-96-4
分子式	C₁₉H₂₁F₂N₇O₂
分子量	417.41
SMILES Code	FC(C1=NC2=CC=CC=C2N1C3=NC(N4CCOCC4)=NC(N5CCOCC5)=N3)F
MDL No.	MFCD08705334

ZSTK474 {[allProObj[0].p_purity_real_show]}

ZSTK474 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

ZSTK474 质控信息

ZSTK474 生物活性

ZSTK474 细胞实验

ZSTK474 动物实验

ZSTK474 临床研究

ZSTK474 参考文献

ZSTK474 实验方案

ZSTK474 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

别名
运输	蓝冰
InChI Key	HGVNLRPZOWWDKD-UHFFFAOYSA-N
Pubchem ID	11647372

p110γ	PI3Kγ, IC50:49 nM
p110β	PI3Kβ, IC50:44 nM
p110α	PI3Kα, IC50:16 nM
PI3K	PI3K, IC50:37 nM
p110δ	PI3Kδ, IC50:4.6 nM

human A549 cells	10 μM	Function assay	1 h	Inhibition of PI3K in human A549 cells assessed as reduction in pAkt level at 10 uM after 1 hr by Western blotting analysis	25766633
human A549 cells		Growth inhibition assay		Growth inhibition of human A549 cells	22336246
human ACHN cells		Growth inhibition assay		Growth inhibition of human ACHN cells	22336246
human DMS114 cells		Growth inhibition assay		Growth inhibition of human DMS114 cells	22336246
human DU145 cells		Growth inhibition assay		Growth inhibition of human DU145 cells	22336246
human HCC2998 cells		Growth inhibition assay		Growth inhibition of human HCC2998 cells	22336246
human HCT116 cells		Function assay	15 mins	Inhibition of PIK3CA H1047R mutant-mediated cell signaling in human HCT116 cells expressing PTEN assessed as inhibition of insulin-induced pAkt/PKB phosphorylation at Thr308 treated for 15 mins before insulin challenge measured after 5 mins by immunoblotting, IC50=78 nM	21882832
human HCT15 cells		Growth inhibition assay		Growth inhibition of human HCT15 cells	22336246
human HT-29 cells		Growth inhibition assay		Growth inhibition of human HT-29 cells	22336246
human KM12 cells		Growth inhibition assay		Growth inhibition of human KM12 cells	22336246
human LNCAP cells		Proliferation assay	3 days	Antiproliferative activity against human LNCAP cells after 3 days by MTS assay, IC50=0.21 μM	20227881
human LOXIMVI cells		Growth inhibition assay		Growth inhibition of human LOXIMVI cells	22336246
human LOXIMVI cells		Growth inhibition assay		Growth inhibition of human LOXIMVI cells	22336246
human MDA-MB-468 cells		Cytotoxic assay	48 h	Cytotoxicity against PTEN-deficient human MDA-MB-468 cells assessed as inhibition of cell growth after 48 hrs by Cell Titer 96 assay	23795239
human MKN74 cells		Growth inhibition assay		Growth inhibition of human MKN74 cells	22336246
human NCI-H226 cells		Growth inhibition assay		Growth inhibition of human NCI-H226 cells	22336246
human NCI-H522 cells		Growth inhibition assay		Growth inhibition of human NCI-H522 cells	22336246
human NZB5 cells		Proliferation assay	5 days	Antiproliferative activity against human NZB5 cells expressing wild type p110alpha assessed as incorporation of [3H]thymidine after 5 days, IC50=0.22 μM	21882832
human NZOV9 cells		Proliferation assay	5 days	Antiproliferative activity against human NZOV9 cells expressing p110alpha kinase Y1021C mutant assessed as incorporation of [3H]thymidine after 5 days, IC50=0.29 μM	21882832
human OVCAR3 cells		Growth inhibition assay		Growth inhibition of human OVCAR3 cells	22336246
human OVCAR4 cells		Growth inhibition assay		Growth inhibition of human OVCAR4 cells	22336246
human OVCAR5 cells		Growth inhibition assay		Growth inhibition of human OVCAR5 cells	22336246
human OVCAR8 cells		Growth inhibition assay		Growth inhibition of human OVCAR8 cells	22336246
human PC3 cells		Growth inhibition assay		Growth inhibition of human PC3 cells	22336246
human SKOV3 cells		Growth inhibition assay		Growth inhibition of human SKOV3 cells	22336246
human SKOV3 cells		Growth inhibition assay		Growth inhibition of human SKOV3 cells	22336246
human SNB75 cells		Growth inhibition assay		Growth inhibition of human SNB75 cells	22336246
human SNB78 cells		Growth inhibition assay		Growth inhibition of human SNB78 cells	22336246
human St-4 cells		Growth inhibition assay		Growth inhibition of human St-4 cells	22336246
Sf21 insect cells		Function assay	1 h	Inhibition of bovine recombinant PI3K p110delta expressed in Sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging, IC50=0.7 nM	21882832

ZSTK474 {[allProObj[0].p_purity_real_show]}

ZSTK474 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

ZSTK474 质控信息

ZSTK474 生物活性

ZSTK474 细胞实验

ZSTK474 动物实验

ZSTK474 临床研究

ZSTK474 参考文献

ZSTK474 实验方案

ZSTK474 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

ZSTK474 纯度/质量文件产品仅供科研